MedTrace Logo

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

NCT05572463 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-11-18

No results posted yet for this study

Summary

This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.

Conditions

  • Unresectable Cutaneous Melanoma
  • Metastatic Cutaneous Melanoma

Interventions

COMBINATION_PRODUCT

Sintilimab + IBI110

IBI110 infusion in combination with Sintilimab (IBI308) infusion will be given on a Q3W schedule

Sponsors & Collaborators

  • Innovent Biologics (USA), Inc.

    collaborator UNKNOWN

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2027-06-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Germany
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05572463 on ClinicalTrials.gov